Genmab – Talk Bio

Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial

1 week ago talkbio0Tagged AbbVie, Diffuse Large B-Cell Lymphoma, DLBCL-1, EPCORE, Epcoritamab, EPKINLY, Genmab, Lymphoma, Overall Survival, Phase 3, Progression-Free Survival

Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival

Genmab Discontinues Phase III Development of Acasunlimab Lung Cancer Asset Previously Ditched by BioNTech

3 weeks ago talkbio0Tagged acasunlimab, BioNTech, Genmab, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Phase 3, Pipeline Review

Genmab; acasunlimab; BioNTech; lung cancer; NSCLC; Phase 3; pipeline review

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

2 months ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond

4 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Breakthrough Therapy, Cancer of Neck, CEO, expansion, Genmab, Head, Merus, Neoplasms, Perspective, Petosemtamab, pipeline, United States Food and Drug Administration

Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective

Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal

4 months ago talkbio0Tagged Acquisition, ADC, Antibody-Drug Conjugates, Genmab, Neoplasms, ProfoundBio, therapeutic autologous dendritic cells

Genmab; ProfoundBio; antibody-drug conjugates; ADC; acquisition; oncology; Rina-S

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

6 months ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Epcoritamab, EPKINLY, expansion, Genmab, Labels (device), lenalidomide, Lymphoma, Follicular, Phase 3 Clinical Trials, rituximab, T-Cell engager, United States Food and Drug Administration

Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide